The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats

British Journal of Pharmacology

Volumn 170, Issue 5, 2013, Pages 1102-1111

  Altamirano Espinoza, A H ^a   Gonzalez Hernandez A ^a   Manrique Maldonado, G ^a   Marichal Cancino, B A ^a   Ruiz Salinas, I ^a   Villalõn, Carlos M ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

cardioaccelerator sympathetic outflow; dopamine D2 like receptors; L 741,626; L 745,870; SB 277011 A; sympathoinhibition; tachycardic responses

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NORADRENALIN; QUINPIROLE; ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRD3 PROTEIN, RAT; DRD4 PROTEIN, RAT;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG SELECTIVITY; HEART INNERVATION; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYMPATHETIC BLOCKING; SYMPATHETIC INNERVATION; TACHYCARDIA; WISTAR RAT; ADRENERGIC SYSTEM; ANIMAL; CARDIOACCELERATOR SYMPATHETIC OUTFLOW; DECEREBRATION; DOPAMINE D2-LIKE RECEPTORS; DRUG EFFECT; ELECTROSTIMULATION; HEART; INNERVATION; INTRAVENOUS DRUG ADMINISTRATION; L-741,626; L-745,870; METABOLISM; SB-277011-A; SYMPATHOINHIBITION; TACHYCARDIC RESPONSES; TIME;

CARDIOACCELERATOR SYMPATHETIC OUTFLOW; DOPAMINE D2-LIKE RECEPTORS; L-741,626; L-745,870; SB-277011-A; SYMPATHOINHIBITION; TACHYCARDIC RESPONSES;

ANIMALS; DECEREBRATE STATE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; HEART; HEART RATE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; NOREPINEPHRINE; QUINPIROLE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOMIMETICS; TIME FACTORS;

EID: 84885574306     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12358     Document Type: Article

References (42)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Beaulieu JM, Gainetdinov RR, (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182-217.
3. Bechtel WD, Mierau J, Pelzer H, (1986). Biochemical pharmacology of pirenzepine. Similarities with tricycle antidepressants in antimuscarinic effects only. Arzeneimittelforschung 36: 793-796.
4. Bessa AM, Zanella T, Saragoca MA, Mulinari RA, Czepielewski M, Ribeiro AB, et al. (1984). Acute hemodynamic and humoral effects of metoclopramide on blood pressure control improvement in subjects with diabetic orthostatic hypotension. Pharmacol Ther 36: 738-744.
5. Boehm S, Kubista H, (2002). Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol Rev 54: 43-99.
6. 2 receptor antagonist L-741,626. Br J Pharmacol 119: 1491-1497.
7. Cavallotti C, Nutti F, Bruzzone P, Mancome M, (2002). Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol 29: 412-418.
8. De Jong AP, Verhage M, (2009). Presynaptic signal transduction pathways that modulate synaptic transmission. Curr Opin Neurobiol 19: 245-254.
9. Gillespie JS, MacLaren A, Pollock D, (1970). A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat. Br J Pharmacol 40: 257-267.
10. Goldberg LI, (1972). Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 24: 1-29.
11. Harvey JN, Worth DP, Brown J, Lee MR, (1985). The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol 19: 21-27.
12. Harvey JN, Worth DP, Brown J, Lee MR, (1986). Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. Br J Clin Pharmacol 21: 53-61.
13. Jose PA, Eisner GM, Felder RA, (2003). Regulation of blood pressure by dopamine receptors. Nephron Physiol 95: 19-27.
14. Kleinman L, Radford E, (1964). Ventilation standards for small mammals. J Appl Physiol 19: 360-362.
15. Kuchel O, Buu NT, Hamet P, Larochelle P, Gutkowska J, Schiffrin EL, et al. (1985). Effect of metoclopramide on plasma catecholamine release in essential hypertension. Clin Pharmacol Ther 37: 372-375.
16. Langer SZ, Vidal M, Duval N, (1987). Presynaptic dopamine receptors in the cardiovascular system. Clin Exp Hypertens 9: 837-851.
17. Lefevre-Borg F, Lorrain J, Lechaire J, Thiry C, Lhoste F, Hicks PE, et al. (1987). Cardiovascular characterization of the DA2 dopamine receptors agonist quinpirole in rats. Fundam Clin Pharmacol 1: 179-200.
18. Li XX, Bek M, Asico LD, Yang Z, Grandy DK, Goldstein DS, et al. (2001). Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension 38: 303-308.
19. Lokhandwala MF, Hegde SS, (1990). Cardiovascular dopamine receptors: role of renal dopamine and dopamine receptors in sodium excretion. Pharmacol Toxicol 66: 237-243.
20. Lozano-Cuenca J, Muñoz-Islas E, González-Hernández A, Centuriõn D, Cobos-Puc LE, Sánchez-Lõpez A, et al. (2009). Pharmacological characterization of the inhibition by dihydroergotamine and methysergide on the cardioaccelerator sympathetic outflow in pithed rats. Eur J Pharmacol 612: 80-86.
21. 2-receptors and effect of oxygen supplementation. Clin Sci 101: 377-383.
22. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
23. Mannelli M, Ianni L, Lazzeri C, Castellani W, Pupilli C, La Villa G, et al. (1999). In vivo evidence that endogenous dopamine modulates sympathetic activity in man. Hypertension 34: 398-402.
24. Mannering D, Bennett ED, Mehta N, Kemp F, (1984). Increased forearm vascular resistance after dopamine blockade. Br J Clin Pharmaco1 17: 373-378.
25. Missale C, Nash S, Robinson S, Jaber M, Caron M, (1998). Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
26. Neve KA, Seamans JK, Trantham-Davidson H, (2004). Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165-204.
27. Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, et al. (1997). Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther 283: 636-647.
28. Polakowski JS, Segreti JA, Cox BF, Hsieh GC, Kolasa T, Moreland RB, et al. (2004). Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol 31: 837-841.
29. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, et al. (2000). Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294: 1154-1165.
30. Roquebert J, Moran A, Sauvage MF, Demichel P, (1992). Effects of quinpirole on autonomic nervous control of heart rate in rats. Fundam Clin Pharmacol 6: 67-73.
31. 3 receptor subtype for mediating the quinpirole-induced inhibition of the vasopressor sympathetic outflow in pithed rats. Naunyn Schmiedebergs Arch Pharmacol 386: 393-403.
32. Sánchez-Lõpez A, Centuriõn D, Vázquez E, Arulmani U, Saxena PR, Villalõn CM, (2003). Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors. Br J Pharmacol 140: 725-735.
33. 1D subtypes. Naunyn Schmiedebergs Arch Pharmacol 369: 220-227.
34. Seeman P, Van Tol MH, (1994). Dopamine receptor pharmacology. Trends Pharmacol Sci 15: 264-270.
35. Shipley RE, Tilden JH, (1947). A pithed rat preparation suitable for assaying pressor substances. Proc Soc Exp Biol Med 64: 453-455.
36. Sigala S, Missale C, Tognazzi N, Spano P, (2000). Differential gene expression of dopamine D-2 receptor subtypes in rat chromaffin cells and sympathetic neurons in culture. Neuroreport 11: 2467-2471.
37. Steel RGD, Torrie JH, (1980). Principles and Procedures of Statistics, a Biomedical Approach, 2nd edn. McGraw-Hill: Kogakusha.
38. 1D subtypes. Br J Pharmacol 124: 1001-1011.
39. Villalõn CM, Centuriõn D, del Mar FM, Morán A, Sánchez-Lõpez A, (1999). 5-Hydroxytryptamine inhibits the tachycardia induced by selective preganglionic sympathetic stimulation in pithed rats. Life Sci 64: 1839-1847.
40. 4, receptor subtypes in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats. Proceedings of the 2011 BPS Winter Meeting. Available at: http://www.pa2online.org/abstract/abstract. jsp?abid=29869&author=villal&cat=-1&period=-1 (accessed 9/17/2013).
41. Wilffert B, Smith G, de Jonge A, Thoolen M, Timmermans P, Van Zwieten P, (1984). Inhibitory dopamine receptors on the sympathetic neurons innervating the cardiovascular system of the pithed rat. Characterization and role in relation to presynaptic alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 326: 91-98.
42. Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG, (1985). Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 37: 165-216.